Interferon type I signaling pathways (WP3213)

Bos taurus

Authors

Martina Summer-Kutmon and Egon Willighagen

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Bos taurus

Communities

Annotations

Pathway Ontology

Jak-Stat signaling pathway immune response pathway

References

1. Tyrosine phosphorylation is required for activation of an alpha interferon-stimulated transcription factor. Gutch MJ, Daly C, Reich NC. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11411–5. PubMed Europe PMC Scholia
2. Soluble interferon-alpha receptor molecules are present in body fluids. Novick D, Cohen B, Rubinstein M. FEBS Lett. 1992 Dec 21;314(3):445–8. PubMed Europe PMC Scholia
3. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Schindler C, Shuai K, Prezioso VR, Darnell JE Jr. Science. 1992 Aug 7;257(5071):809–13. PubMed Europe PMC Scholia
4. A transcription factor with SH2 and SH3 domains is directly activated by an interferon alpha-induced cytoplasmic protein tyrosine kinase(s). Fu XY. Cell. 1992 Jul 24;70(2):323–35. PubMed Europe PMC Scholia
5. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Uzé G, Lutfalla G, Gresser I. Cell. 1990 Jan 26;60(2):225–34. PubMed Europe PMC Scholia
6. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3’-kinase. Uddin S, Yenush L, Sun XJ, Sweet ME, White MF, Platanias LC. J Biol Chem. 1995 Jul 7;270(27):15938–41. PubMed Europe PMC Scholia
7. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, Pitha P, et al. J Biol Chem. 1995 Sep 15;270(37):21606–11. PubMed Europe PMC Scholia
8. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. Beadling C, Guschin D, Witthuhn BA, Ziemiecki A, Ihle JN, Kerr IM, et al. EMBO J. 1994 Dec 1;13(23):5605–15. PubMed Europe PMC Scholia
9. The human interferon alpha/beta receptor: characterization and molecular cloning. Novick D, Cohen B, Rubinstein M. Cell. 1994 May 6;77(3):391–400. PubMed Europe PMC Scholia
10. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Müller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, et al. Nature. 1993 Nov 11;366(6451):129–35. PubMed Europe PMC Scholia
11. Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. Colamonici OR, Domanski P. J Biol Chem. 1993 May 25;268(15):10895–9. PubMed Europe PMC Scholia
12. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. David M, Chen HE, Goelz S, Larner AC, Neel BG. Mol Cell Biol. 1995 Dec;15(12):7050–8. PubMed Europe PMC Scholia
13. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. Platanias LC, Uddin S, Yetter A, Sun XJ, White MF. J Biol Chem. 1996 Jan 5;271(1):278–82. PubMed Europe PMC Scholia
14. Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction. Yan H, Krishnan K, Lim JT, Contillo LG, Krolewski JJ. Mol Cell Biol. 1996 May;16(5):2074–82. PubMed Europe PMC Scholia
15. Interaction of the c-cbl proto-oncogene product with the Tyk-2 protein tyrosine kinase. Uddin S, Gardziola C, Dangat A, Yi T, Platanias LC. Biochem Biophys Res Commun. 1996 Aug 23;225(3):833–8. PubMed Europe PMC Scholia
16. Interaction of p59fyn with interferon-activated Jak kinases. Uddin S, Sher DA, Alsayed Y, Pons S, Colamonici OR, Fish EN, et al. Biochem Biophys Res Commun. 1997 Jun 9;235(1):83–8. PubMed Europe PMC Scholia
17. STATs and gene regulation. Darnell JE Jr. Science. 1997 Sep 12;277(5332):1630–5. PubMed Europe PMC Scholia
18. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. Owczarek CM, Hwang SY, Holland KA, Gulluyan LM, Tavaria M, Weaver B, et al. J Biol Chem. 1997 Sep 19;272(38):23865–70. PubMed Europe PMC Scholia
19. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, et al. J Biol Chem. 1997 Sep 26;272(39):24183–90. PubMed Europe PMC Scholia
20. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Uddin S, Fish EN, Sher D, Gardziola C, Colamonici OR, Kellum M, et al. Blood. 1997 Oct 1;90(7):2574–82. PubMed Europe PMC Scholia
21. The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. Ahmad S, Alsayed YM, Druker BJ, Platanias LC. J Biol Chem. 1997 Nov 28;272(48):29991–4. PubMed Europe PMC Scholia
22. Inhibition of Stat1-mediated gene activation by PIAS1. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10626–31. PubMed Europe PMC Scholia
23. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. Song MM, Shuai K. J Biol Chem. 1998 Dec 25;273(52):35056–62. PubMed Europe PMC Scholia
24. Activation of a CrkL-stat5 signaling complex by type I interferons. Fish EN, Uddin S, Korkmaz M, Majchrzak B, Druker BJ, Platanias LC. J Biol Chem. 1999 Jan 8;274(2):571–3. PubMed Europe PMC Scholia
25. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. You M, Yu DH, Feng GS. Mol Cell Biol. 1999 Mar;19(3):2416–24. PubMed Europe PMC Scholia
26. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Platanias LC, Uddin S, Bruno E, Korkmaz M, Ahmad S, Alsayed Y, et al. Exp Hematol. 1999 Aug;27(8):1315–21. PubMed Europe PMC Scholia
27. Activation of the p38 mitogen-activated protein kinase by type I interferons. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, et al. J Biol Chem. 1999 Oct 15;274(42):30127–31. PubMed Europe PMC Scholia
28. Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. Farrar JD, Smith JD, Murphy TL, Murphy KM. J Biol Chem. 2000 Jan 28;275(4):2693–7. PubMed Europe PMC Scholia
29. Involvement of the Gab2 scaffolding adapter in type I interferon signalling. Baychelier F, Nardeux PC, Cajean-Feroldi C, Ermonval M, Guymarho J, Tovey MG, et al. Cell Signal. 2007 Oct;19(10):2080–7. PubMed Europe PMC Scholia
30. Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock. Samarajiwa SA, Mangan NE, Hardy MP, Najdovska M, Dubach D, Braniff SJ, et al. J Immunol. 2014 May 1;192(9):4425–35. PubMed Europe PMC Scholia